The Promise of Preventive Cancer Vaccines

Vaccines

Pier-Luigi Lollini²  Federica Cavallo¹  Patrizia Nanni²  Elena Quaglino¹ 

[1] Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Via Nizza 52, Torino 10126, Italy; E-Mails:;Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, Viale Filopanti 22, Bologna 40126, Italy; E-Mail:

关键词: cancer vaccines;    cancer immunoprevention;    cancer immunotherapy;    Her2;    immune checkpoint inhibitors;   

DOI  :  10.3390/vaccines3020467

来源: mdpi

【 摘 要 】

Years of unsuccessful attempts at fighting established tumors with vaccines have taught us all that they are only able to truly impact patient survival when used in a preventive setting, as would normally be the case for traditional vaccines against infectious diseases. While true primary cancer prevention is still but a long-term goal, secondary and tertiary prevention are already in the clinic and providing encouraging results. A combination of immunopreventive cancer strategies and recently approved checkpoint inhibitors is a further promise of forthcoming successful cancer disease control, but prevention will require a considerable reduction of currently reported toxicities. These considerations summed with the increased understanding of tumor antigens allow space for an optimistic view of the future.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.